Entero Therapeutics (Nasdaq: ENTO)
Pharmaceutical Manufacturing • 
Boca Raton, Florida, United States • 1-10 Employees
Company overview
| Headquarters | 777 Yamato Road, Suite 502, Boca Raton, FL 33431, US |
| Phone number | +15615897020 |
| Website | |
| NAICS | 3254 |
| Keywords | Therapeutics, Gluten-Free, Gastrointestinal, Cystic Fibrosis, Gastroparesis, Gluten, Celiac Disease, Pancreatitis, Celiac, Gi Health, Gluten-Free Diet, Gluten Intolerance, Lipase, Gastrointestinal Diseases, Gi Diseases, Adrulipase, Capeserod, Latiglutenase |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
Key Contact at Entero Therapeutics (Nasdaq: ENTO)
Catherine Labarca-Cohen
Director Of Human Resources
Entero Therapeutics (Nasdaq: ENTO) Email Formats
Entero Therapeutics (Nasdaq: ENTO) uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@azurrx.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@azurrx.com | 100% |
About Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visitwww.enterothera.com. Entero Therapeutics is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Entero’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively. Entero is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.firstwavebio.com.
Entero Therapeutics (Nasdaq: ENTO) revenue & valuation
| Annual revenue | $855,550 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $2,800,000 |
| Total funding | $9,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Entero Therapeutics (Nasdaq: ENTO) has 4 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Entero Therapeutics (Nasdaq: ENTO)'s funding history, including investment rounds, total capital raised, and key backers.
Entero Therapeutics (Nasdaq: ENTO) Tech Stack
Discover the technologies and tools that power Entero Therapeutics (Nasdaq: ENTO)'s digital infrastructure, from frameworks to analytics platforms.
CDN
CMS
Search engines
JavaScript libraries
Tag managers
Hosting
Reverse proxies
Programming languages
Security
Miscellaneous
JavaScript graphics
JavaScript libraries
United Arab Emirates
Spain
United Kingdom
Canada
Frequently asked questions
4.8
40,000 users
